TNFRSF4 and sarcoma: In cancer therapy, the beneficial results of combination immunotherapy targeting both costimulatory and co-inhibitory molecules (combined OX40/PD-1 or OX40/CTLA-4 mAb therapy) dramatically improved survival in the prostate, ovarian carcinoma, and sarcoma models (70, 75).